Teva realignment sees oncology programs divested
This article was originally published in Scrip
Teva Pharmaceutical has signed over worldwide rights to four oncology programs to San Diego-based Ignyta. The move comes after Teva conducted a strategic review of its core therapeutic areas under new CEO Erez Vigodman. This resulted in the decision, announced last October, to move away from oncology and woman's health and focus CNS and respiratory diseases.